Uporedite metode

	PASI (Psoriasis Area and Severity Index)	EASI (Indeks površine i težine ekcema)	SCORAD indeks (SCORing Atopic Dermatitis)
Oblast	Dermatologija	Dermatologija	Dermatologija
Porodica	Process / pipeline	Process / pipeline	Process / pipeline
Godina nastanka	1978	2001	1993
Tvorac	Fredriksson T, Pettersson U	Hanifin JM, Thurston M	European Task Force on Atopic Dermatitis (ETFAD)
Tip	Clinician-rated	Clinician-rated	Clinician-rated
Temeljni izvor	Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-244.	Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Experimental Dermatology. 2001;10(1):11-18.	Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10-19.
Drugi nazivi	PASI Index	EASI Index	SCORAD Index
Srodne	2	2	3
Sažetak	The PASI is the gold-standard clinician-administered measure of psoriasis severity and extent. Developed by Fredriksson and Pettersson in 1978, it evaluates four cardinal clinical signs (erythema, induration, desquamation) across four body regions, each weighted by anatomical importance. PASI is the most widely used endpoint in psoriasis clinical trials and is endorsed by regulatory agencies (FDA, EMA) and international dermatology societies.	The EASI is a structured, clinician-administered tool for assessing the extent and intensity of atopic dermatitis across the body. Developed by Hanifin and colleagues in 2001, it divides the body into four regions with weighted area factors, ensuring proportional contribution to total score. EASI has become the primary objective severity measure in atopic dermatitis clinical trials and is recommended by international regulatory authorities (FDA, EMA).	The SCORAD is a comprehensive clinician-administered tool for measuring the extent and severity of atopic dermatitis (eczema). Developed by the European Task Force on Atopic Dermatitis in 1993, it combines objective clinical assessment with subjective symptom reporting. It is the gold standard for atopic dermatitis severity in clinical trials and dermatology practice.